文献速递白血病MDS 与骨髓增殖性肿瘤

NFE2活性改变易导致白血病转化及伴AML特异性异常的髓肉瘤

Altered NFE2 activity predisposes to leukemic transformation and myelosarcoma with AML-specific aberrations.
PubMed 文献 · Blood · 2019-02-12

研究报道急性髓系白血病(AML)患者和髓肉瘤患者中存在转录因子NFE2突变,并发现表达突变NFE2的小鼠在随访中34%转化为白血病(伴或不伴髓肉瘤)或发生孤立性髓肉瘤,这些肿瘤获得AML特异性改变,包括8三体小鼠等效、5q染色体AML常见缺失区丢失和Trp53突变,表明NFE2突变易导致继发性改变,促进髓肉瘤和/或AML发生。

要点

  • AML患者及髓肉瘤患者中检测到NFE2突变并进行功能鉴定。
  • 表达突变NFE2的小鼠34%在随访中转化为白血病或发生髓肉瘤。
  • 小鼠肿瘤获得AML特异性改变:8三体等效、5q缺失区丢失、Trp53突变。

核心结论

  • NFE2突变易导致继发性改变,促进髓肉瘤和/或AML的发生。

研究设计与样本

  • 研究对AML患者和髓肉瘤患者中的NFE2突变进行存在性检测和功能鉴定,并随访表达突变NFE2的小鼠。

主要发现

  • 随访中34%的表达突变NFE2小鼠转化为白血病(伴或不伴髓肉瘤)或发生孤立性髓肉瘤。
  • 这些髓肉瘤和白血病获得AML特异性改变,包括8三体的小鼠等效、5q染色体上AML常见缺失区的丢失以及抑癌基因Trp53突变。

关键数值与推荐

  • 表达突变NFE2的小鼠中34%在随访期间转化为白血病或发生髓肉瘤。
  • 小鼠肿瘤中检测到8三体等效、5q AML常见缺失区丢失和Trp53突变。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In acute myeloid leukemia (AML), acquired genetic aberrations carry prognostic implications and guide therapeutic decisions. Clinical algorithms have been improved by the incorporation of novel aberrations. Here, we report the presence and functional characterization of mutations in the transcription factor NFE2 in patients with AML and in a patient with myelosarcoma. We previously described NFE2 mutations in patients with myeloproliferative neoplasms and demonstrated that expression of mutant NFE2 in mice causes a myeloproliferative phenotype. Now, we show that, during follow-up, 34% of these mice transform to leukemia presenting with or without concomitant myelosarcomas, or develop isolated myelosarcomas. These myelosarcomas and leukemias acquired AML-specific alterations, including the murine equivalent of trisomy 8, loss of the AML commonly deleted region on chromosome 5q, and mutations in the tumor suppressor Trp53 Our data show that mutations in NFE2 predispose to the acquisition of secondary changes promoting the development of myelosarcoma and/or AML.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Jutzi JS, Basu T, Pellmann M, et al. Altered NFE2 activity predisposes to leukemic transformation and myelosarcoma with AML-specific aberrations. Blood. 2019. PMID: 30755419. doi:10.1182/blood-2018-09-875047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。